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The series of European cost of illness studies presented in this volume aims at 
updating the information on the average annual cost for patients with multiple 
sclerosis (MS) at different stages of the disease. The number of participating 
countries has been increased compared to earlier studies, making it the largest 
study ever carried out. A summary of the studies has been published earlier this 
year.1  
 
A total of 16,808 patients in 16 countries was included and data were collected 
directly from patients. This allowed the inclusion of all relevant costs (health care 
and health services, workforce participation, out of pocket expenses and family 
help), as well as disease-related information and health-related quality of life 
(HRQoL). Such complete information is currently not available in any dataset or 
registry. The ambition of this study was to illustrate how costs and HRQoL 
change as the disability increases rather than total costs of MS in a country. All 
results are presented by disease severity. This provides important information as 
treatment in MS aims at slowing this worsening and thus reducing costs in the 
long term.     
 
It is striking to notice a number of similarities and differences in these European 
countries. While MS affects people in very much the same way across the 
continent (Figure 1), its management differs considerably Figure 2.1. Reasons for 
this  may be found in differences in economic wealth, availability of services, 
clinical approaches and beliefs, and national characteristics. They cannot be 
explained by differences in the samples. Even a mean age difference of 20 years 
and a mean disability difference of 2.6 EDSS points in the samples cannot 
explain a ten-fold difference in inpatient and day case admissions; a range from 
60-90% of patients with consultations in a quarter or a range of 25-81% of 
patients who see a neurologist; a difference of 5-35% in the proportions of 
patients who get an MRI or a range of 26-80% who are on treatment with DMTs. 
Highlighting these facts will hopefully lead to questions being raised and 
subsequently addressed. 
 
For the first time in such a large survey, patients have been asked to assess the 
level of fatigue, extent of cognitive difficulties and the effect of MS while working. 
In view of the large number of participants, the results are very powerful. The 
overwhelming presence of fatigue, while known, may have been underestimated 
in the past. Irrespective of the country, 95% of patients felt fatigue was an issue, 
with a mean level of 5-6 on a scale from 0 to 10, regardless of the severity of the 
disease. Similarly, cognitive difficulties were recognized by over 70% of patients, 
with a severity of 4-5, again irrespective of disability and country. Finally, anxiety 
appears to be present at the same levels in all countries and at all stages of the 
disease. These findings argue for more focus on and more effective management 
of these aspects of the condition.   
 
The data in this study series provide a wealth of information on the current 
situation in MS provided by a large number of patients. They are important for 
clinicians, health technology assessment agencies, policy makers and, not least, 
for patient organisations who, in this case, are also the owners of the data. The 
large amount of patient-level data should trigger more research activity in a 
number of areas, including into the determinants of costs. Overall it is hoped that 
they will contribute to adopting a more effective approach to management which 
will result in better outcomes for patients.  
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Figure 1 – Utility scores related to EDSS levels in 16 countries 
 
 
 
Reprinted with permission, Kobelt et al, Multiple Sclerosis 2017.1  
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Figure 2 – Mean annual cost per patient related to EDSS levels in 16 countries 
 
 
 
 
Reprinted with permission, Kobelt et al, Multiple Sclerosis 2017.1 
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